Food and Drug Administration has issued warning letters to 30 telehealth companies for making false or misleading ‌claims ...

Metabolic syndrome (MetS) is a complex condition characterized by obesity, dyslipidemia, and hypertension, and is closely linked to inflammation. It serves ...

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such ...

About 4% of GLP-1 users developed osteoporosis, compared with a little over 3% of nonusers — an increased risk of about 30%. A related condition, osteomalacia, which involves the softening of the ...

Since 2021, the story of GLP-1s has illustrated that scientific progress is rarely a straight line from hypothesis to patient ...

The first daily GLP-1 pill for weight loss, oral semaglutide, marketed as Wegovy, was launched in the US last year, expanding access to obesity treatment beyond injections.

Mittal said the opportunity remains meaningful despite the broader GLP-1 market shifting toward newer therapies such as ...

Obesity among adults and children in the US is still on the rise, despite the boom of weight-loss medications like Ozempic, a shocking new report released by the CDC has found.

Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

BACKGROUND: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type 2 diabetes, including individuals with and those without a history of heart ...